-

Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments

AI-powered supply chain orchestration and rare-disease innovation join forces for faster delivery of critical therapies to patients in need

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration today announced that Swedish Orphan Biovitrum AB (Sobi), a leading international biopharmaceutical company, has elected to implement the Kinaxis Maestro® platform to facilitate end-to-end collaboration across its partner network, enable data-driven decisions and support the delivery of critical therapies to patients with rare diseases.

“Sobi will utilize Maestro to unlock real-time collaboration and seamless execution in order to fast-track the delivery of critical therapies worldwide.”

Share

With a mission to serve 95% of rare diseases that still lack approved treatments, Sobi operates in a complex and urgent field of healthcare. Headquartered in Stockholm, Sweden, Sobi specializes in hematology, immunology and specialty care, delivering innovative treatments to over 40,000 patients annually across 55 countries. Sobi’s operations have a direct impact on the quality of life of patients suffering from rare conditions – requiring a high degree of speed, precision and visibility across its supply chain.

Maestro’s advanced capabilities in scenario planning, centralized data management and attribute-based planning will support Sobi to strengthen partner connectivity, scale operations, and respond faster to potential disruptions to facilitate the supply of critical therapies for rare diseases to patients with high medical needs.

“Kinaxis is well-regarded in the life sciences sector for its understanding of the unique complexities of supply chains that define this specific industry,” said Norbert Schoellhorn, vice president of global manufacturing and supply chain at Sobi. “We believe that Kinaxis will help us connect better with our partners, respond faster to change and deliver life-changing treatments to patients who can’t afford to wait.”

“Sobi’s work changes lives, and we’re proud to support them in delivering on that mission,” said Fabienne Cetre, executive vice president of EMEA at Kinaxis. “Sobi will utilize Maestro to unlock real-time collaboration and seamless execution in order to fast-track the delivery of critical therapies worldwide.”

Kinaxis is a leading supply chain technology partner for life sciences companies globally including Merck, Novartis, Bristol Myers Squibb, Cardinal Health, Boston Scientific, Servier and more. Deloitte Nordics will lead the implementation of Maestro. To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc

Contacts

Media Relations
Erin Boyle | Kinaxis
eboyle@kinaxis.com
+1 519-574-4065

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613

Industry:

Kinaxis Inc.

TSX:KXS
Release Versions
EnglishSpanishPortugueseGermanFrenchItalian (Summary)Dutch (Summary)Chinese TraditionalChinese SimplifiedJapanese

Contacts

Media Relations
Erin Boyle | Kinaxis
eboyle@kinaxis.com
+1 519-574-4065

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613

Social Media Profiles
Kinaxis LinkedIn
More News From Kinaxis Inc.

71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis

OTTAWA, Ontario--(BUSINESS WIRE)--According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact. Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and jus...

Kinaxis Inc. Reports Third Quarter 2025 Results

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, reported results for its third quarter ended September 30, 2025. All amounts are in U.S. dollars. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated. “Our momentum continues as record new business for a third quarter drove accelerated ARR growth and allows us to confidently target even stronger results for fiscal 2...

Kinaxis Announces Normal Course Issuer Bid

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the C...
Back to Newsroom